Cochrane · systematic review · CD002311

Late (≥ 7 days) inhaled corticosteroids to reduce bronchopulmonary dysplasia in preterm infants

Onland, W, Offringa, M, van Kaam, A · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library

Neonatal2 versionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 4 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Questions and results

Show all 2 versions

Inhaled corticosteroids compared to placebo in preterm infants

Population: preterm infants
4 questions
OutcomeEffectEvidenceStatus / GRADE
Combined outcome of mortality or BPD at 36 weeks' PMA
Inhaled corticosteroids vs placebo
RR 1.1 [0.74, 1.63]1 study · 30 participantsVery low
Downgraded: imprecision, inconsistency, publication bias
Mortality at 36 weeks' PMA
Inhaled corticosteroids vs placebo
RR 3 [0.35, 25.78]3 studies · 61 participantsVery low
Downgraded: imprecision, publication bias
BPD at 36 weeks' PMA
Inhaled corticosteroids vs placebo
RR 1 [0.59, 1.7]1 study · 30 participantsVery low
Downgraded: imprecision, inconsistency, publication bias
Open‐label use of systemic corticosteroids
Inhaled corticosteroids vs placebo
RR 0.51 [0.26, 1]4 studies · 74 participantsVery low
Downgraded: imprecision, inconsistency